ibrutinib

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

BTK inhibitor

Related drugs:

Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: A1 - Approval J&J Press Release - 1 week (New A1) venetoclax + ibrutinib Sensitive : A1 J&J Press Release - 1wk	venetoclax + ibrutinib Sensitive: A1 - Approval J&J Press Release - 1 week venetoclax + ibrutinib Sensitive : A1 J&J Press Release - 1 week - (New A1)
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: A1 - Approval J&J Press Release - 1 week (New A1) venetoclax + ibrutinib Sensitive : A1 J&J Press Release - 1wk	venetoclax + ibrutinib Sensitive: A1 - Approval J&J Press Release - 1 week venetoclax + ibrutinib Sensitive : A1 J&J Press Release - 1 week - (New A1)
CD79B mutation	Lymphoma	CD79B mutation	Lymphoma	ibrutinib Sensitive: C3 – Early Trials Adv Clin Exp Med - 3 weeks (New C3) ibrutinib Sensitive : C3 Adv Clin Exp Med - 3wk	ibrutinib Sensitive: C3 – Early Trials Adv Clin Exp Med - 3 weeks ibrutinib Sensitive : C3 Adv Clin Exp Med - 3 weeks - (New C3)
MYD88 mutation	Lymphoma	MYD88 mutation	Lymphoma	ibrutinib Sensitive: C3 – Early Trials Adv Clin Exp Med - 3 weeks (New C3) ibrutinib Sensitive : C3 Adv Clin Exp Med - 3wk	ibrutinib Sensitive: C3 – Early Trials Adv Clin Exp Med - 3 weeks ibrutinib Sensitive : C3 Adv Clin Exp Med - 3 weeks - (New C3)
PIM1 mutation	Lymphoma	PIM1 mutation	Lymphoma	ibrutinib Sensitive: C3 – Early Trials Adv Clin Exp Med - 3 weeks (New C3) ibrutinib Sensitive : C3 Adv Clin Exp Med - 3wk	ibrutinib Sensitive: C3 – Early Trials Adv Clin Exp Med - 3 weeks ibrutinib Sensitive : C3 Adv Clin Exp Med - 3 weeks - (New C3)
TMB-L	Lymphoma	TMB-L	Lymphoma	ibrutinib Sensitive: C3 – Early Trials Adv Clin Exp Med - 3 weeks (New C3) ibrutinib Sensitive : C3 Adv Clin Exp Med - 3wk	ibrutinib Sensitive: C3 – Early Trials Adv Clin Exp Med - 3 weeks ibrutinib Sensitive : C3 Adv Clin Exp Med - 3 weeks - (New C3)
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ibrutinib + obinutuzumab Sensitive: A1 - Approval ibrutinib + obinutuzumab Sensitive : A1	ibrutinib + obinutuzumab Sensitive: A1 - Approval ibrutinib + obinutuzumab Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2
IGH mutation	Chronic Lymphocytic Leukemia	IGH mutation	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	ibrutinib + rituximab + lenalidomide Sensitive: A2 - Guideline ibrutinib + rituximab + lenalidomide Sensitive : A2	ibrutinib + rituximab + lenalidomide Sensitive: A2 - Guideline ibrutinib + rituximab + lenalidomide Sensitive : A2
No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 deletion	Chronic Lymphocytic Leukemia	TP53 deletion	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	pembrolizumab + nivolumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + nivolumab + ibrutinib Sensitive : A2	pembrolizumab + nivolumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + nivolumab + ibrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	pembrolizumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + ibrutinib Sensitive : A2	pembrolizumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + ibrutinib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	pembrolizumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + ibrutinib Sensitive : A2	pembrolizumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + ibrutinib Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	pembrolizumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + ibrutinib Sensitive : A2	pembrolizumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + ibrutinib Sensitive : A2
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	BR + ibrutinib Sensitive: A2 - Guideline BR + ibrutinib Sensitive : A2	BR + ibrutinib Sensitive: A2 - Guideline BR + ibrutinib Sensitive : A2
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	BR + ibrutinib Sensitive: A2 - Guideline BR + ibrutinib Sensitive : A2	BR + ibrutinib Sensitive: A2 - Guideline BR + ibrutinib Sensitive : A2
TP53 deletion	Small Lymphocytic Lymphoma	TP53 deletion	Small Lymphocytic Lymphoma	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2
No biomarker	Lymphoma	No biomarker	Lymphoma	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2

ibrutinib

Associations
(172)

Associations
(172)

ibrutinib

Associations(172)

Associations(172)

Associations
(172)

Associations
(172)